Characterisation and application of recombinant FVIII‐neutralising antibodies from haemophilia A inhibitor patients
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17227
Abstract: The development of anti‐drug antibodies (ADAs) is a serious outcome of treatment strategies involving biological medicines. Coagulation factor VIII (FVIII) is used to treat haemophilia A patients, but its immunogenicity precludes a third of severe… read more here.
Keywords: application recombinant; fviii; characterisation application; fviii neutralising ... See more keywords
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.591878
Abstract: The most severe side effect of hemophilia treatment is the inhibitor development occurring in 30% of patients, during the earliest stages of treatment with factor (F)VIII concentrates. These catastrophic immune responses rapidly inactivate the infused… read more here.
Keywords: inhibitor; fviii products; treatment; fviii ... See more keywords